XML 113 R15.htm IDEA: XBRL DOCUMENT v3.20.1
Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests
 3 Months Ended
Mar. 29, 2020
Equity [Abstract]  
Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests
The following table provides the changes, net of tax, in Accumulated other comprehensive loss:
 
 
Net Unrealized Gains/(Losses)
 
Benefit Plans
 
 
(MILLIONS OF DOLLARS)
 
Foreign Currency Translation Adjustments

 
Derivative Financial Instruments

 
Available-For-Sale Securities

 
Actuarial Gains/(Losses)

 
Prior Service (Costs)/Credits and Other

 
Accumulated Other Comprehensive Income/(Loss)

Balance, December 31, 2019
 
$
(5,952
)
 
$
20

 
$
(35
)
 
$
(6,257
)
 
$
584

 
$
(11,640
)
Other comprehensive income/(loss)(a)
 
(1,020
)
 
(364
)
 
(32
)
 
(39
)
 
(35
)
 
(1,490
)
Balance, March 29, 2020
 
$
(6,973
)
 
$
(344
)
 
$
(67
)
 
$
(6,296
)
 
$
549

 
$
(13,131
)
(a) 
Includes after-tax losses of approximately $1.2 billion related to foreign currency translation adjustments attributable to our equity method investment in GSK Consumer Healthcare (see Note 2B), partially offset by the results of our net investment hedging program.
As of March 29, 2020, with respect to derivative financial instruments, the amount of unrealized pre-tax net gains on derivative financial instruments, which are included in Accumulated Other Comprehensive Loss, estimated to be reclassified into income within the next 12 months is approximately $294 million. The net gains are expected to be offset primarily by net losses from foreign currency exchange-denominated forecasted intercompany inventory sales upon the sale of the inventory to a third party.